业绩预增
Search documents
禾盛新材发预增,预计2025年归母净利润1.52亿元至1.71亿元,增长55%至75%
Zhi Tong Cai Jing· 2026-01-20 14:57
禾盛新材(002290)(002290.SZ)披露2025年度业绩预告,公司预计归属于上市公司股东的净利润1.52亿 元至1.71亿元,同比增长55%至75%;归属于上市公司股东的扣除非经常性损益的净利润1.52亿元至1.17 亿元,同比增长52.82%至72.55%。 公告称,2025年度公司预计归属上市公司股东净利润上升的原因为:公司加强供应链管理,带动公司产 品毛利率较上年同期增长。 ...
燕京啤酒发预增,预计2025年度归母净利润15.84亿元至17.42亿元,同比增长50%-65%
Zhi Tong Cai Jing· 2026-01-20 12:48
Core Viewpoint - Yanjing Beer (000729.SZ) has disclosed its earnings forecast for the year 2025, projecting a significant increase in net profit attributed to shareholders, indicating strong growth potential in the company's financial performance [1] Financial Performance - The company expects net profit attributable to shareholders to be between 1.584 billion and 1.742 billion yuan, representing a year-on-year growth of 50% to 65% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 1.457 billion and 1.561 billion yuan, reflecting a year-on-year increase of 40% to 50% [1]
泰山石油(000554.SZ)发预增,预计2025年归母净利润1.3亿元至1.65亿元,同比增长30.88%-66.11%
智通财经网· 2026-01-20 12:10
Core Viewpoint - Taishan Petroleum (000554.SZ) forecasts a net profit attributable to shareholders of 130 million to 165 million yuan for the year 2025, representing a year-on-year growth of 30.88% to 66.11% [1] - The company expects a net profit of 134 million to 169 million yuan after deducting non-recurring gains and losses, indicating a year-on-year increase of 23.39% to 55.74% [1] Summary by Category - **Financial Performance** - The projected net profit for 2025 is between 130 million and 165 million yuan, with a growth rate of 30.88% to 66.11% year-on-year [1] - The expected net profit after excluding non-recurring items is between 134 million and 169 million yuan, reflecting a growth of 23.39% to 55.74% year-on-year [1] - **Operational Changes** - In 2024, the company will update and renovate old equipment and facilities at oil depots and charging stations, leading to significant increases in repair and safety production costs compared to the same period [1] - The expenses related to these updates are expected to decrease in 2025, contributing to profit growth [1] - The company will implement cost reduction and efficiency enhancement measures in 2025, which are anticipated to further boost profits [1]
甘肃能源发预增,预计2025年度归母净利润19.5亿元至21亿元,增长18.60%至27.72%
Zhi Tong Cai Jing· 2026-01-20 12:00
Group 1 - The company Gansu Energy (000791.SZ) has disclosed its performance forecast for the year 2025, expecting a net profit attributable to shareholders of between 1.95 billion yuan and 2.1 billion yuan, representing a year-on-year growth of 18.60% to 27.72% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 1.96 billion yuan and 2.11 billion yuan, indicating a significant year-on-year increase of 172.28% to 193.12% [1]
甘肃能源(000791.SZ)发预增,预计2025年度归母净利润19.5亿元至21亿元,增长18.60%至27.72%
智通财经网· 2026-01-20 11:57
Core Viewpoint - Gansu Energy (000791.SZ) has disclosed its performance forecast for the year 2025, indicating a significant increase in net profit attributed to shareholders [1] Financial Performance - The company expects net profit attributable to shareholders to be between 1.95 billion and 2.1 billion yuan, representing a year-on-year growth of 18.60% to 27.72% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 1.96 billion and 2.11 billion yuan, showing a substantial year-on-year increase of 172.28% to 193.12% [1]
恒通股份预计2025年归母净利润同比增超60% 拟注销前期回购股份并启动新一轮回购
Zheng Quan Ri Bao Wang· 2026-01-20 11:49
Core Viewpoint - Hengtong Logistics Co., Ltd. (Hengtong Shares) has announced significant performance growth for 2025, alongside changes in share repurchase plans and capital reduction, reflecting a positive development trend and commitment to shareholder returns [1][2][3] Financial Performance - Hengtong Shares expects a net profit attributable to shareholders of 250 million to 280 million yuan for 2025, representing a year-on-year increase of 61.22% to 80.57% [1] - The net profit, excluding non-recurring gains and losses, is also projected to be between 250 million and 280 million yuan, with a growth rate of 63.47% to 83.09% [1] - The primary driver for this performance increase is the operational commencement of production berths by its wholly-owned subsidiary, Shandong Yulong Port Co., Ltd., leading to a significant rise in port throughput and utilization rates [1] Share Repurchase and Capital Reduction - The company plans to change the purpose of 8.3649 million shares repurchased in 2024 from employee stock ownership plans to capital reduction, which will be submitted for shareholder approval [2] - Following the cancellation of these shares, the total share capital will decrease from 714 million shares to 706 million shares [2] Investor Confidence and Market Strategy - The company aims to enhance investor confidence and protect shareholder interests through these measures [3] - A new share repurchase plan has been approved, with a total fund of no less than 80 million yuan and no more than 100 million yuan, at a maximum price of 14.50 yuan per share, with all repurchased shares intended for cancellation [3] - The simultaneous announcement of performance growth and the "old share cancellation + new share repurchase" strategy sends multiple positive signals to the market, indicating management's confidence in the company's future prospects [3]
宇瞳光学发预增,预计2025年度归母净利润2.4亿元至2.8亿元,增长30.75%至52.54%
Zhi Tong Cai Jing· 2026-01-20 11:21
Core Viewpoint - Yutong Optical (300790.SZ) has disclosed its performance forecast for the year 2025, expecting a net profit attributable to shareholders of between 240 million yuan and 280 million yuan, representing a year-on-year growth of 30.75% to 52.54% [1] Financial Performance - The company anticipates a net profit after deducting non-recurring gains and losses to be between 235 million yuan and 275 million yuan, indicating a year-on-year increase of 47.40% to 72.48% [1]
晶品特装:2025年营收预增64.90%至95.43%,仍处亏损状态
Xin Lang Cai Jing· 2026-01-20 11:17
Core Viewpoint - The company expects a significant increase in revenue for the fiscal year 2025, alongside a reduction in net losses compared to the previous year [1] Revenue Forecast - The company projects total revenue for 2025 to be between 270 million and 320 million yuan, representing an increase of 106 million to 156 million yuan year-on-year, which corresponds to a growth of 64.90% to 95.43% [1] Profitability Outlook - The net profit attributable to the parent company is expected to range from a loss of 22 million to 11 million yuan, which indicates a reduction in losses by 35.19 million to 46.19 million yuan compared to the previous year, translating to a year-on-year decrease in losses of 61.53% to 80.77% [1] Factors Influencing Performance - The performance changes are primarily attributed to increased revenue, improved cost control, and better collection of receivables leading to a reversal of credit impairment losses. However, the company still faces losses due to price adjustments and inventory write-downs [1]
本川智能(300964.SZ)发预增,预计2025年度归母净利润3040万元至4560万元,增长28.06%至92.08%
智通财经网· 2026-01-20 11:17
Core Viewpoint - The company, Benchuan Intelligent (300964.SZ), has disclosed its performance forecast for the year 2025, indicating a significant increase in net profit attributed to shareholders. Group 1: Financial Performance - The company expects a net profit attributable to shareholders ranging from 30.4 million to 45.6 million yuan, representing a year-on-year growth of 28.06% to 92.08% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 26.4 million and 39.6 million yuan, with a year-on-year increase of 55.56% to 133.35% [1]
昭衍新药发预增,预计2025年度归母净利润同比增加约214%到371%
Zhi Tong Cai Jing· 2026-01-20 11:11
Core Viewpoint - Zhaoyan New Drug (603127.SH) forecasts a net profit attributable to shareholders of approximately RMB 233 million to RMB 349 million for the year 2025, representing a year-on-year increase of about 214% to 371% [1] Group 1: Financial Performance - The increase in fair value is driven by a rise in market prices of biological assets and natural growth appreciation [1] - The laboratory operations have maintained a stable performance during the reporting period [1] Group 2: Revenue and Profitability - Due to the previous intense industry competition, the revenue and gross margin from performance contracts have decreased year-on-year [1] - The contribution of laboratory service business profits has declined [1]